Version 1
: Received: 21 June 2024 / Approved: 21 June 2024 / Online: 21 June 2024 (14:43:51 CEST)
How to cite:
Ljungström, M.; Oltra, E.; Pardo, M. Stress-Related Chronic Fatigue Syndrome: A Case Report with Positive Response to Alpha-Methyl-P-Tyrosine (AMPT) Treatment. Preprints2024, 2024061544. https://doi.org/10.20944/preprints202406.1544.v1
Ljungström, M.; Oltra, E.; Pardo, M. Stress-Related Chronic Fatigue Syndrome: A Case Report with Positive Response to Alpha-Methyl-P-Tyrosine (AMPT) Treatment. Preprints 2024, 2024061544. https://doi.org/10.20944/preprints202406.1544.v1
Ljungström, M.; Oltra, E.; Pardo, M. Stress-Related Chronic Fatigue Syndrome: A Case Report with Positive Response to Alpha-Methyl-P-Tyrosine (AMPT) Treatment. Preprints2024, 2024061544. https://doi.org/10.20944/preprints202406.1544.v1
APA Style
Ljungström, M., Oltra, E., & Pardo, M. (2024). Stress-Related Chronic Fatigue Syndrome: A Case Report with Positive Response to Alpha-Methyl-P-Tyrosine (AMPT) Treatment. Preprints. https://doi.org/10.20944/preprints202406.1544.v1
Chicago/Turabian Style
Ljungström, M., Elisa Oltra and Marta Pardo. 2024 "Stress-Related Chronic Fatigue Syndrome: A Case Report with Positive Response to Alpha-Methyl-P-Tyrosine (AMPT) Treatment" Preprints. https://doi.org/10.20944/preprints202406.1544.v1
Abstract
Alpha-methyl-p-tyrosine (AMPT; also referred as metyrosine) is an approved medication for the treatment of pheochromocytoma. As a tyrosine hydroxylase inhibitor AMPT may be a potential candidate for the treatment of diseases involving catecholamine alterations. However, only small-scale clinical trials have tested AMPT repurposing in few other illnesses. Chronic fatigue syndrome (CFS) is an heterogenous disorder with genetically associated vulnerability of catecholamine metabolism (e.g. catechol O-methyltransferase polymorphisms) holding an important impact of environmental factors. The current case report compiles genetic and longitudinal biochemical data for over a year follow-up of one patient sequentially diagnosed with sustained overstress, neurasthenia, CFS, and POTS (postural orthostatic tachycardia syndrome) over a 10-year period, and reports patient’s symptom improvement in response to low-medium doses of AMPT.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
